Pharmaceutical patents: how to protect the intellectual property of a healthcare innovation?
Intellectual property protection is the foundation of any healthcare innovation strategy. In a demanding sector where research and development mobilize considerable resources, securing each technological advance from the outset guarantees the sustainability of investment and the future competitiveness of a drug, device, manufacturing process, or innovative technology.
The strategic importance of patents in medical innovation
The development of a new drug requires years of research and considerable investment. Only strong protection guarantees a return on these commitments.
A patent grants an exclusive exploitation right for twenty years from the filing date. It thus provides legal protection against copying and creates a valuable asset for investors.
When applying for marketing authorization for an innovative product, the presence of a solid intellectual property portfolio has a significant impact on the economic evaluation of the project.
Financial and partnership leverage
A title issued by the European Patent Office increases the credibility of a pharmaceutical startup, a decisive factor when seeking capital.
Recent analyses of financing options for biotechnology startups show a clear correlation between valuation and intellectual property portfolio. Furthermore, licensing a patented invention provides a flexible tool for negotiating industrial alliances without transferring the underlying intellectual property.
A pillar of regulatory competitiveness
Competition also depends on speed of execution.
Compressing the timeline, in line with strategies to reduce drug development time, maximizes the period of commercial protection before the title expires.
This advantage is in addition to the exclusive rights already granted.
Patentability requirements for health inventions
Patent law imposes three criteria:
- Novelty,
- Inventive step,
- Industrial application.
If satisfied, they provide access to a European patent or a national patent.
Patent-eligible inventions
The following may be protected:
- Active ingredients;
- Gene therapy vectors;
- Innovative medical devices;
- Manufacturing processes;
- Artificial intelligence algorithms dedicated to diagnosis.
On the condition, however, that they generate a measurable technical effect. An optimized antibody purification process, combined with a new high-capacity adsorbent material, illustrates, for example, this type of advance.
Exclusions and Ethics
The human body in its natural state, therapeutic methods applied directly to the patient, and discoveries lacking technical application are not patentable. The Myriad Genetics case serves as a reminder that a raw genomic sequence1 is in the public domain.
A genomic sequence refers to the exact order of nucleotides (A, T, C, G) constituting an organism’s DNA. It therefore represents the “map” of genetic information.
The guidelines of the World Intellectual Property Organization urge careful distinction between discovery and invention, otherwise patents will be rejected during examination.
Patent filing process
The preparatory phase requires exhaustive document monitoring: WIPO (World Intellectual Property Organization), EPO (European Patent Office) databases, and national registers.
This step, prior to patent filing, avoids overlaps and refines the drafting.
Writing and filing
A precise brief, written by an industrial property attorney, defines the invention while covering potential variants.
The patent application can be filed with the INPI (French National Institute of Industrial Property), the EPO, or, to target multiple jurisdictions, through the Patent Cooperation Treaty (PCT).
This route retains international priority for thirty months, allowing time to select key markets.
Examination and grant
The application is published 18 months after the filing date. Only after this publication does the office managing the procedure begin substantive examination.
Formal exchanges address potential objections.
Grant then confers exclusivity, subject to annual payment of fees.
Lifecycle management and extension
The actual lifespan is reduced by the drug’s development time.
Supplementary protection certificate (SPC)
To compensate for this gap, the supplementary certificate adds up to five years of industrial property protection. It is only issued if the substance is already covered by a patent that is still in force, if the marketing authorization invoked is the first in the State concerned, if the application is filed within six months of this marketing authorization (or the grant of the patent, whichever is later), and if no SPC has yet been granted for this product. A six-month pediatric extension may be added.
Secondary patents
An improvement in formulation, a new therapeutic indication, or the refinement of a manufacturing process may be the subject of a second filing. Each new patent strengthens protection and complicates market access for competitors.
Patents, generics, biosimilars, and post-exclusion competition
The expiration of the primary patent paves the way for generics and biosimilars.
The anticipated developments for biosimilar drugs within the European Union are increasing competitive pressure.
Companies are therefore anticipating this by developing patented improvements that delay market share erosion.
The post-patent period also requires optimizing the duration of regulatory data protection, which is distinct from intellectual property rights but just as crucial for market access. Some companies are extending their differentiation by launching modified-release formulations or claiming new therapeutic indications resulting from targeted clinical research.
Others are relying on industrial know-how, protected by secrecy, to maintain a technological advantage that is difficult to replicate.
Actively monitoring competitors’ development programs and registration procedures makes it possible to anticipate the arrival of a generic or biosimilar product and prepare a structured commercial response.
Recourse to litigation, however, remains an option.
Acting for infringement or to assert a complementary exclusive right can indeed delay a rival’s entry until the dispute is settled.
These combined approaches, integrated into a comprehensive industrial property protection strategy, ensure a controlled transition between the exclusivity period and the open competition phase.
Summary
Securing a medical invention requires rigorous scheduling: technological monitoring, expert writing, careful selection of patent offices, and anticipation of the exploitation period.
The patent-regulatory tandem ensures that the product reaches the market within the exclusivity window.
At the same time, the constant evolution of intellectual property laws, European directives, and international initiatives requires continuous vigilance.
In a field where every advance can be life-changing, the robustness of a patent remains the essential foundation of healthcare technology.
